A method of preparing epinephrine or norepinephrine is provided. The method includes reacting a starting material comprising 2-chloro-l-(3,4-dihydroxyphenyl)ethan-l- one with an amine nucleophile RNH2 (R=H for the synthesis of epinephrine or Me for the synthesis of norepinephrine) under conditions suitable for nucleophilic substitution of the starting material to form a substituted starting material and reacting the substituted starting material with a tethered ligand transition metal catalyst under conditions suitable for transfer¬ hydrogenation to produce epinephrine or norepinephrine.
C07C 215/46 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
C07C 215/56 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
C07C 213/00 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
C07C 215/58 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
C07C 213/10 - SeparationPurificationStabilisationUse of additives
2.
NEW PROCESS FOR PHENYLEPHRINE AND SALBUTAMOL AND RELATED COMPOUNDS VIA ASYMETRIC TRANSFER HYDROGENATION OF UNPROTECTED AMINO KETONES
Methods for the preparation of asymmetrically reduced compounds such as (R)- phenylephrine and (R)- salbutamol) are provided. The methods comprise two steps: 1) nucleophilic substitution of a halogenated starting material to form an unprotected amino ketone, followed by 2) asymmetric transfer hydrogenation of the unprotected amino ketone. The methods are advantageously performed under mild conditions, e.g. at ambient pressure.
C07C 213/02 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
C07C 225/06 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and acyclic
C07C 225/04 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
Bio-artificial blood substitutes are provided for intravenous medical use to restore or increase tissue perfusion and oxygen delivery in a pre-hospital or hospital setting. The bio-artificial blood substitutes comprise three modular components (polyethylene glycol (PEG) polymers to increase perfusion, a hemoglobin-based oxygen carrier (HBOC) plus L-arginine to prove oxygen carrying capacity, and a lyophilized fibrinogen or plasma component to provide hemostasis potential, all of which are administered sequentially in modules to treat low perfusion states with possible coagulopathy as seen in blood loss and shock. The three solutions are stable at ambient temperature and are well-suited for use in the field, e.g., when immediate, critical care is needed such as on the battlefield, during natural disasters or other mass casualty events. Other use may include clinical need for transfusion or for peri-surgical resuscitation in patients unable to receive standard blood products.
Methods of detecting cysteine-containing peptides are provided. The methods include steps of contacting a resistive-pulse nanopore sensing system with a sample containing cysteine-containing peptides of at least 10 amino acid residues in length, wherein the resistive-pulse nanopore sensing system comprises thiolate-capped gold clusters arranged in a cis side of nanopores and detecting a change in current indicative of exchange between a cysteine-containing peptide and the thiolate-capped gold clusters.
An example device for repairing a tissue is described herein. The device can include a flexible carrier layer, and a support member including a plurality of micro-protrusions extending therefrom. The support member can be at least partially integrated with the flexible carrier layer. Additionally, the flexible carrier layer can be configured to cover at least a portion of the tissue, and the micro-protrusions can be configured to mechanically interface with the tissue.
A method of delivering an active ingredient to a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a formulation comprising biodegradable, polymeric microparticles and an active ingredient selected from the group consisting of levo-alpha-acetylmethadol (LAAM), nor-LAAM, and dinor-LAAM, wherein the active ingredient is part of a hydrophobic ion-pairing (HIP) complex and wherein the HIP complex is associated with the microparticles. Sustained release formulations containing an active ingredient are also provided.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Methods for treating liver cancer in a patient are provided. The methods include steps of administering at least one dose of a therapeutically effective amount of a composition comprising indocyanine green (ICG) and applying a PDT light source to the liver of the patient, wherein the PDT light source comprises a transarterial fiber optic coaxial catheter comprising a laser light, a sheet having an array of light-emitting diode (LED) lights, or a micro-injectable LED implant configured for delivery inside the liver, wherein the PDT light source is applied for a time period sufficient to release reactive oxygen species from the photosensitizing agent and induce apoptosis of cancer cells. A PDT system may include a composition comprising ICG and a PDT device comprising at least one light source enabled for application of light to a target tumor.
A series of non-peptide mu opioid receptor (MOR) selective modulators is provided. The compounds have the general formula (I) where R is (II) and where one of a, b, c, d, e or f is the point of attachment of indole ring R to the epoxymorphinan skeleton; at least one of the atoms at positions a, b, c, d, e and f is N; the remaining atoms at positions at a, b, c, d, e and f are CH; and * is a chiral carbon. The compounds are generally MOR antagonists and are used to treat disorders related to opioid receptor functions such as opioid addiction and opioid overdose, for the treatment of neurological diseases and for the treatment of pain, without causing constipation.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61P 25/04 - Centrally acting analgesics, e.g. opioids
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A method of decellularizing in an animal tissue includes digesting the animal tissue; treating the animal tissue with a surfactant: treating the animal tissue with at least one zwitterionic detergent to form a decellularized animal tissue; and treating the decellularized animal tissue with at least one advanced glycation end-product (AGE) inhibitor to reduce AGE crosslinking in the decellularized animal tissue. The decellularized animal tissue may be ground into a powder and dissolved in a digest solution to form a bioink composition useful for 3D printing an in vitro model of healthy or diseased tissue.
Provided is a functionalized polymer useful for extracting, isolating, and/or purifying membrane proteins with their native protein structures being retained. Also provided are a Native Cell Membrane Nanoparticle (NCMN) system which contains the above functionalized polymer and a membrane protein and a method to characterize and/assess the native structure of the membrane protein.
C08G 81/02 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
11.
FIRE-RESISTANT, FIRE RETARDANT AND/OR THERMAL INSULATION
An open cell foam, and particularly aerogels or other foams, having an inorganic, hydraded phase change material (PCM) embedded within pores or cells or a network within the foam have fire retardant, fire resistant and thermal insulating properties. These composite materials are preferably monolithic in character, and are mechanically robust allowing for example the attachment of nails or screws. With the PCM distributed throughout the open cell foam, the composite material has a wide array of applications including providing thermal, fire resistant, and fire retardant uses in battery containers, in automotives and other vehicles, etc.
C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
C09K 5/14 - Solid materials, e.g. powdery or granular
F16L 59/02 - Shape or form of insulating materials, with or without coverings integral with the insulating materials
12.
BENZALDEHYDE COMPOUNDS WITH DIRECT POLYMER DESTABILIZING EFFECTS TO TREAT SICKLE CELL DISEASE
Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
13.
ELASTOMERIC SILK FIBROIN AND METHODS OF MAKING THE SAME
An elastomeric material which combines fibroin and siloxane exhibits high strength and flexibility while simultaneously being suitable for applications requiring biodegradability or cytocompatibility. An exemplary material is made from a combination of photocurable precursors - a photocurable fibroin and a photocurable siloxane. Hexafluoroisopropanol is used as a co-solvent with photocurable fibroin and photocurable polysiloxane. A cured film or coating is usable in dry and wet conditions. Various organic and/or electronic materials may be patterned on exemplary materials using techniques such as photolithography and screen printing.
C07K 1/107 - General processes for the preparation of peptides by chemical modification of precursor peptides
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A neonatal circumcision training model serves as a life-like penis model on which medical practitioners may train in circumcision procedures. An exemplary model includes simulants of glans and shaft of the penis covered by a fascia-analog layer and a skin-analog layer. The layers are distinct and separable from one another and facilitate training medical professionals to spot the facia layer and distinguish it from the skin layer.
Provided herein are compounds and pharmaceutical compositions for treating cancer (e.g., melanoma), and methods of use thereof. The compounds disclosed herein inhibit MDA-9/Syntenin by binding both MDA-9/Syntenin PDZ domains.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
The technology is based on a conducting, ferromagnetic ink made from, in an aqueous suspension: conducting nanopolymers, ferromagnetic nanoparticles, an adhesion promoter and optionally, a surfactant and/or stabilizer. The ink is used to form reversible physical and electrical connections between e.g., rigid and flexible devices. In some aspects, the conducting nanopolymers are PEDOT:PSS (poly(3,4-ethylenedioxythiophene) polystyrene sulfonate) nanopolymers and the magnetic nanoparticles are iron oxide nanoparticles. The ink, which may be magnetic, is used to form solid, flexible, ferromagnetic conducting designs or nodes which may also be magnetic. The flexible, ferromagnetic conducting designs or nodes are used to form reversible magnetic electrical connections with devices such as potentiostats and data telemetry devices.
The present disclosure provides fusion proteins of IL-24 with immunostimulatory cytokines and natural killer (NK) cells genetically engineered to express IL-24 or such fusion proteins, and methods of using these proteins and cells.
Sanford Burnham Prebys Medical Discovery Institute (USA)
Inventor
Fisher, Paul B.
Pellecchia, Maurizio
Das, Swadesh K.
Kegelman, Timothy P.
Wu, Bainan
De, Surya K.
Wei, Jun
Menezes, Mitchell E.
Emdad, Luni
Abstract
Provided herein are, inter alia, compositions that bind to a PDZI domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.
A robotic gripper is capable of withstanding the high temperatures of processes such as metal additive manufacturing. One or more of the fingers of the gripper include a casted ceramic insulator with a steel finger backing. Industrial thermocouples may attach to a finger for active temperature monitoring. An exemplary robotic gripper is adaptive, usable on a collaborative robot, and temperature resistant to over 1000° C. without introducing costly augmentations such as liquid cooling.
Provided herein is a magnetic tunnel junction (MTJ) based non-volatile non-binary matrix multiplier comprising a straintronic MTJ “multiplier” and a spin-orbit torque driven MTJ “accumulator”. The multiplier quantity (one element of one matrix) and the multiplicand quantity (one element of the other matrix) are encoded in voltage pulses that are applied across two different sets of the straintronic MTJ terminals to produce a MTJ current output that is proportional to the product of the multiplier and multiplicand.
G06G 7/16 - Arrangements for performing computing operations, e.g. amplifiers specially adapted therefor for multiplication or division
G11C 11/16 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements using elements in which the storage effect is based on magnetic spin effect
H10B 61/00 - Magnetic memory devices, e.g. magnetoresistive RAM [MRAM] devices
Mu opioid receptor (MOR) antagonists that specifically and effectively reverse the acute and chronic toxicity of fentanyl and its analogs are provided. The antagonists were developed by modifying the structural skeleton of fentanyl and/or phenylfentanil. The antagonists compete with fentanyls at the MOR binding site and when bound, they reverse the toxicity of fentanyls more effectively and selectively or specifically than naloxone, naltrexone, and other epoxymorphinan-type opioids.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
Sputtering machines and substrate holders for such systems are described which include one or more magnets apart from the magnets typical of sputtering guns. The added magnets produce a magnetic field bias which is a new means for controlling depositional flux. ionization degree of a sputtered species. and microstructure properties of deposited coatings. An exemplary substrate holder may have a magnet or magnet array near or next to the surface supporting the substrate, and the magnet may assume multiple different magnetic field configurations depending on the desired properties of the resulting magnetic field bias within the reaction chamber.
Examples include an artificial conductive cilia based sensor having, on a substrate, a conductive pad and a neighbor conductive pad spaced in a direction. A first conductive cilium has a distal end, and a base end conductively secured to the conductive pad, and is particularly structured with bendability and elasticity. A second conductive cilium has a base end conductively secured to the neighbor conductive pad. A terminal is electrically connected to the conductive pad. Another terminal is electrically connected to the neighbor conductive pad. The first conducive cilium, in accordance with the bendability, is bent by a bending force directed in the spacing direction, to a bent state configured to establish a conductive path to the second conductive cilium and via the elasticity, to self-return to a relaxed state configured to terminate the conductive path.
G01F 1/54 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow by using mechanical effects by means of chains, flexible bands, or wires introduced into, and moved by, the flow
B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
VIRGINIA COMMONWEALTH UNIVERSITY (USA)
Inventor
Neuwelt, Alexander
Bryan, Allyn
Abstract
The disclosure relates to compositions including acetaminophen or analogs thereof and CYP2E1 -inhibitors suitable for parenteral or oral administration. Methods of treating cancer in subjects by administering acetaminophen or analogs thereof and CYP2E1 -inhibitors are also included.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61P 35/04 - Antineoplastic agents specific for metastasis
C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Various embodiments of the present disclosure are directed to systems and methods of developing a self-optimizing regression model for identifying multiple analytes from complex mixtures. A system can perform a method of generating a model based at least in part on a plurality of calibration spectra; applying the model to at least one test spectrum corresponding to a test sample; and determining component concentrations of the test sample based at least in part on the application of the model.
Synthetic mini circular RNA vaccine constructs are provided. The synthetic mini circular RNA constructs encode one or more antigens and are used, for example, as vaccines against cancer or infectious agents. In some aspects, the one or more antigens are translated as concatemer peptides by rolling cycle translation (RCT) of the mini circular RNA.
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
27.
POLYGENIC RISK ESTIMATOR FOR CERVICAL LENGTH CHANGE DURING PREGNANCY
A method for determining, for a woman, the risk of a premature short cervical length (sCL), and hence preterm birth, is provided. The method comprises measuring gene allelic variation in a biological sample obtained from the woman, developing a polygenic risk score (PRS), and identifying the woman as having an increased risk for sCL and preterm birth if the PRS is higher than that of corresponding standard controls. Methods for the prophylactic treatment of women identified as being at increased risk are also provided.
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
Provided herein is a self-calibrating electrochemical sensor, which includes an indicator electrode, a reference electrode. and a calibration bridge that connects the indicator electrode and the reference electrode. The calibration bridge has an ion-conducting or electron-conducting phase that establishes a pre-measuring baseline electrochemical signal. When the sample to be tested is introduced to the sensor, the change in the electrochemical signal relative to the baseline is used to detect and/or quantify the analyte in the sample. The built-in calibration phase does not need to be removed when the sample is tested.
Anatomically accurate brain phantoms are physical models of brains which mimic the viscoelastic properties of brain tissues. The material used to represent different layers of the brain may be a composition of a hydrogel solution and a cross-linking agent, with ratios calculated and determined to accurately reflect the brain's mechanical properties, most notably, the viscoelasticity. Embedded sensors (e.g., accelerometers) measure impact forces and shear stresses/strains caused by a concussion-related experimental impact to the phantom. Uses of the hydrogel brain phantom include biomedical research and as a planning tool for medical treatments. A specific subject's brain may be replicated for designing personalized treatment.
Disclosed are various approaches for calculating crystal orientation via dark-field images from an electron microscope. In some examples, a system includes an electron microscope, at least one computing device comprising a processor and a memory, and machine-readable instructions stored in the memory. The instructions can cause the computing device to at least capture a plurality of dark-field images via the electron microscope. The computing device can calculate a crystal orientation based at least in part on data obtained from the dark-field images. The computing device can further generate an orientation map based at least in part on the crystal orientation.
G01N 23/20058 - Measuring diffraction of electrons, e.g. low energy electron diffraction [LEED] method or reflection high energy electron diffraction [RHEED] method
G01N 23/2251 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material using electron or ion microprobes using incident electron beams, e.g. scanning electron microscopy [SEM]
H01J 37/28 - Electron or ion microscopesElectron- or ion-diffraction tubes with scanning beams
31.
METHODS AND COMPOSITIONS FOR DETERMINATION NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH)
A three-dimensional (3D) topological insulator (Tl), configured with a surface channel for conducting spin polarized electron flow, and piezoelectric element that strains the 3D Tl, responsive to an input voltage, producing stress in the surface channel according to a voltage- to-stress characteristic (VTSC). A spin polarizer and spin analyzer act as source and drain and produce an electric field through the surface channel when a voltage is applied between the source and drain, the spin polarizer injects spin polarized electrons to flow through the surface channel and arrive at the spin analyzer as arrival electrons. The surface channel has a stress-to-rotation characteristic (STRC) that, responsive to the stress, rotates the spin polarization such that the arrival electrons have a rotated plane of polarization, at a rotation angle.
A polymer-assisted 3D printing method and ink compositions are used to manufacture magnetocaloric devices having many applications including in heat pumps, refrigerators, etc. The ink compositions and printing methods can produce compositionally graded, anisotropically aligned magnetocaloric architectures with designed pores and channels, to bring forth significant improvement in heat exchange efficiency.
B22F 1/105 - Metallic powder containing lubricating or binding agentsMetallic powder containing organic material containing inorganic lubricating or binding agents, e.g. metal salts
B22F 1/107 - Metallic powder containing lubricating or binding agentsMetallic powder containing organic material containing organic material comprising solvents, e.g. for slip casting
B22F 5/10 - Manufacture of workpieces or articles from metallic powder characterised by the special shape of the product of articles with cavities or holes, not otherwise provided for in the preceding subgroups
B22F 10/50 - Treatment of workpieces or articles during build-up, e.g. treatments applied to fused layers during build-up
B22F 10/60 - Treatment of workpieces or articles after build-up
B33Y 40/20 - Post-treatment, e.g. curing, coating or polishing
B33Y 70/00 - Materials specially adapted for additive manufacturing
B33Y 80/00 - Products made by additive manufacturing
H01F 1/01 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties of inorganic materials
The present invention relates to compounds derived from 2-benzyloxyphenylethylamines of formula (I) and the pharmaceutically acceptable salts thereof. The invention also relates to the preparation of said compounds by means of a pathway that allows halogenated derivatives to be obtained. The obtained compounds exhibit biological inhibition activity on the human serotonin transporter (hSERT).
C07C 211/02 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
C07D 317/48 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61P 25/00 - Drugs for disorders of the nervous system
Bivalent ligands which bind to MOR-CCR5 heterodimers are provided. The bivalent ligands comprise two discrete pharmacophores, naltrexone and maraviroc, linked by a spacer and bind to MOR-CCR5 heterodimers, e.g. at the surface of a cell. The bivalent ligands are useful in assays to detect MOR-CCR5 heterodimers, as therapeutic agents to prevent and/or treat diseases characterized by the presence of MOR-CCR5 heterodimers.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
36.
ULTRASONIC ELECTROSPINNING FOR THE PRODUCTION OF FINE AND ULTRAFINE FIBERS
Systems, devices, and methods employ advantages of ultrasonic vibration in the field of electrospinning. Fibers are produced from an ultrasonic nozzle exposed to an electric field established between the nozzle and a target object. Exemplary embodiments include electrospinning techniques that produce fine and ultrafine fibers in a high throughput via multiple jetting of spun solutions and melts. Ultrasonic vibration, in some instances combined with heating, reduces the voltage required for spinning. Vibrating power delivered to the nozzle may be selected so gas bubbles are generated by solvent cavitation in the spun solution. The bubbles are generated at the nozzle exit or else in such positions of the solution path so as to reach the nozzle exit where they further enhance multiple jetting of spun solutions.
An example device for repairing a tissue is described herein. The device can include a flexible carrier layer, and a support member including a plurality of micro-protrusions extending therefrom. The support member can be at least partially integrated with the flexible carrier layer. Additionally, the flexible carrier layer can be configured to cover at least a portion of the tissue, and the micro-protrusions can be configured to mechanically interface with the tissue.
A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/24 - Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
A61B 5/388 - Nerve conduction study, e.g. detecting action potential of peripheral nerves
A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
VIRGINIA COMMONWEALTH UNIVERSITY (USA)
Inventor
Gartenhaus, Ronald, B.
Kellogg, Glen, E.
Kapadia, Bandish, B.
Kayastha, Forum, B.
Herrington, Noah, B.
Abstract
The present disclosure is concerned with substituted triazole 4-carbohydrazide compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in, for example, the treatment of cancers such as sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanomas, gliomas, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).
C07D 239/26 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
40.
BENZALDEHYDE COMPOUNDS WITH DIRECT POLYMER DESTABILIZING EFFECTS TO TREAT SICKLE CELL DISEASE
Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are chemically modified to increase bioavailability and activity, e.g., so that the compounds prevent adhesion and sickling of red blood cells (RBCs).
Chimeric recombinant proteins for the detection of infection by Borreliella and/or diagnosis of Lyme disease are provided. Methods and devices for conducting immunoassays with the chimeric recombinant proteins are also provided.
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
C07K 14/20 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
42.
IMMUNOSTIMULATORY CYCLIC DI-NUCLEOTIDE DELIVERY SYSTEM COMPOSITIONS AND METHOD OF USE THEREOF
Provided herein are pH-responsive nanovaccines (NVs) that stimulate the immune system. The NVs comprise nano- or micro-particles to which CDN-modified i-motif DNA is attached. When endocytosed within a subject to whom they are delivered, the change in pH to an acidic environment cause the CDNs to be released from the NVs. The CDNs are STING (stimulator of interferon genes) agonists and after their release, they bind to and activate STING, a critical step in stimulating the immune system. The NVs are used e.g. for cancer immunotherapy, to treat viral infections and/or as vaccine adjuvants.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Borreliella Borreliella and/or diagnosis of Lyme disease are provided. Methods and devices for conducting immunoassays with the chimeric recombinant proteins are also provided.
Liquid compositions containing at least one S-nitrosothiol (RSNO), such as S-nitroso-N- acetylpenicillamine (SNAP) and S -nitrosoglutathione (GSNO), and at least one alkanediol or alkanediol oligomer/polymer are provided. To modulate the rate of release of NO, metal ion chelators may be added to reduce RSNO reactivity or chemical catalysts of RSNO decomposition may be added to increase RSNO reactivity. To suppress formation of undesirable nitrogen oxide species such as NO2, bases or reducing agents may be added. Methods of delivering nitric oxide to a subject and treating respiratory diseases by administering the liquid compositions are also provided.
C08K 5/43 - Compounds containing sulfur bound to nitrogen
B29C 64/112 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using individual droplets, e.g. from jetting heads
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
45.
FIRE-RESISTANT, FIRE RETARDANT AND/OR THERMAL INSULATION
An open cell foam, and particularly aerogels or other foams, having an inorganic, hydraded phase change material (PCM) embedded within pores or cells or a network within the foam have fire retardant, fire resistant and thermal insulating properties. These composite materials are preferably monolithic in character, and are mechanically robust allowing for example the attachment of nails or screws. With the PCM distributed throughout the open cell foam, the composite material has a wide array of applications including providing thermal, fire resistant, and fire retardant uses in battery containers, in automotives and other vehicles, etc.
C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
C09K 5/14 - Solid materials, e.g. powdery or granular
F16L 59/02 - Shape or form of insulating materials, with or without coverings integral with the insulating materials
The invention features methods of treating a SARS-CoV-2 infection in a subject, the method comprising administering to the subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof.
An open cell foam, and particularly aerogels or other foams, having an inorganic, hydraded phase change material (PCM) embedded within pores or cells or a network within the foam have fire retardant, fire resistant and thermal insulating properties. These composite materials are preferably monolithic in character, and are mechanically robust allowing for example the attachment of nails or screws. With the PCM distributed throughout the open cell foam, the composite material has a wide array of applications including providing thermal, fire resistant, and fire retardant uses in battery containers, in automotives and other vehicles, etc.
C09K 5/06 - Materials undergoing a change of physical state when used the change of state being from liquid to solid or vice-versa
B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
B32B 5/18 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by features of a layer containing foamed or specifically porous material
C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
C08J 9/35 - Composite foams, i.e. continuous macromolecular foams containing discontinuous cellular particles or fragments
The invention features methods of treating glioblastoma in a subject, the method comprising administering to the subject an effective amount of sepiapterin or a pharmaceutically acceptable salt thereof.
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
3 β-hydroxy-5-cholestenoic acid 3-sulfate (CA3S), a sulfated derivative of 3β-hydroxy-5-cholestenoic acid (CA), is provided. Both CA and CA3S have potent cholesterol and triglyceride lowering and anti-inflammatory activities. Methods of using CA and CA3S to lower lipids and prevent or treat inflammation-associated diseases are also provided.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
50.
NOVEL CHIMERIC MULTI-PROTEIN BASED RECOMBINANT VACCINE ANTIGENS FOR PREVENTION OF LYME DISEASE IN ANIMALS AND HUMANS
A vaccine formulation for humans or other mammals (including dogs, horses, and cats) is provided. The vaccine formulation includes two chimeric proteins designed to elicit antibodies that bind to several targets on the surface of Lyme disease spirochetes during their residence in ticks and in mammals, and act synergistically to kill the bacteria through both antibody-mediated complement dependent and complement-independent mechanisms.
C07K 14/20 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
An origami-inspired 3D printed in vitro culture platform is fabricated using a ferrous or ferrous-ferric matrix, such as a FesCri NPs/cellulose acetate (CA), to provide a hinged scaffold in which cells can migrate under changing directions of gravity. The platform portions of the hinged scaffold enable the control of pre- and post-culture time before and after folding, allowing for the observation of planar cell migration in microchannels and vertical cell migration between the vertically aligned channels. Platform characterization demonstrated favorable surface morphology, wettability, appropriate compressive stiffness for cell proliferation, noticeably decreased degradation, and acceptable low iron toxicity. Optimizing foldability with varying scaffold architecture and concentration of magnetic particles allowed precise alignment between the top and bottom faces. By applying an external magnetic field, the magnetic property of the NPs allows for the scaffold's folding, enabling temporospatial dynamic cell culture proliferation and migration.
Ursolic acid (UA) preparations and a self-nanoemulsifying drug delivery system (SNEDDS) composition containing at least one UA preparation selected from monopotassium ursolate (UAK), dipotassium ursolate (UAK2), monocholine ursolate (UAmC), dicholine ursolate (UAdC), pharmacological salts thereof, and mixtures thereof are provided. Methods for synthesizing UA preparations and delivering UA preparations to subjects in need thereof are also provided.
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
53.
3D-PRINTABLE ONE-PART CARBON PARTICLE ELASTOMER INK FOR APPLICATIONS SUCH AS HEALTH MONITORING
3D printable inks are disclosed which include one-part room temperature vulcanized (RTV) silicone and carbon particles such as carbon nanotubes (CNTs). Butyl acetate may be used as a solvent to disperse the CNTs in the silicone in the ink precursor. The one-part nature of the inks (i) enables to print without prior mixing and cures under ambient conditions; (ii) allows directly dispensing 100 μm resolution printability on nonpolar and polar substrates; and (iii) forms both self-supporting and high-aspect-ratio structures, key aspects in additive biomanufacturing that eliminate the need for sacrificial layers; and (iv) lends efficient, reproducible, and highly sensitive responses to various tensile and compressive stimuli. The high electrical and thermal conductivity of the CNT-silicone composite is further extended to facilitate use as a flexible and stretchable heating element, with applications in body temperature regulation, water distillation, and a dual temperature sensor and Joule heating source, for example.
Exemplary embodiments of the present disclosure can include, for example, an atomic force microscopy (AFM) system, including a cantilever(s), an optical pickup unit(s) (OPU(s)) including a laser positioned over the cantilever(s), and a power source providing noise with a noise level that is below 300 Picometers. The noise level of the power source can be below 200
Exemplary embodiments of the present disclosure can include, for example, an atomic force microscopy (AFM) system, including a cantilever(s), an optical pickup unit(s) (OPU(s)) including a laser positioned over the cantilever(s), and a power source providing noise with a noise level that is below 300 Picometers. The noise level of the power source can be below 200
Picometers. A digitizing arrangement can be included which can be associated with the OPU. The digitizing arrangement(s) can have a bandwidth of about 2 MHZ. The OPU(s) can have a detection bandwidth of at least 80 MHZ. The exemplary apparatus can be combined with a chemical protocol and statistical signal processing and image analysis procedures to map DNA at high speed and accuracy.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
Analgesic compounds which bind to multiple opioid receptors are provided, e.g., they bind to both the mu opioid receptor (MOR) and the kappa opioid receptor (KOR). The compounds are effective in relieving pain without causing addiction, and thus have a low or no potential for abuse.
Dry powder inhalers (DPIs) and related platforms are disclosed with a passive cyclic loading mode of operation. Metering elements such as a powder shelf may be used to control the amount of powder that is aerosolized with each actuation. Advantages of the passive cyclic loading system include metering a consistent amount of powder for each actuation while protecting the powder in the reservoir from aggregate formation. A single device can accommodate a variable range of powder doses and aerosolize a relatively consistent amount of dose with each actuation, while remaining insensitive to the amount of powder loaded (above a certain threshold).
A combined flossing and interproximal brushing dental device, comprising: a handle having a proximal end and a distal end, wherein the proximal end is configured to be held by a user; a first arm; a second arm; dental floss engaging members positioned at or towards a free end of the first arm and at or towards a free end of the second arm, wherein said first arm and said second arm are spaced apart on the handle and the dental floss engaging members are configured to hold dental floss, extending between the first arm and the second arm; and an interproximal brush forming all or a part of the first arm.
A method for producing a purified morphinan-glycoside conjugate. The method includes the steps of contacting a morphinan compound with an activated saccharide or activated oligosaccharide and a glycosyltransferase in a reaction mixture under conditions, including any co-factors necessary for glycosyltransferase activity, effective to produce a morphinan-glycoside conjugate; and purifying the morphinan-glycoside conjugate from the reaction mixture to obtain the isolated morphinan-glycoside conjugate. Compounds, compositions, conjugates, and methods for their use are also provided.
C12P 19/60 - Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
C07H 17/00 - Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
C12P 19/18 - Preparation of compounds containing saccharide radicals produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
Described herein are methods for preventing a relapse of cancer in a subject. The methods involve administering to the subject in need thereof a sulfated glycosaminoglycan or the pharmaceutically acceptable salt or ester thereof. In one aspect, the methods described herein prevent the growth or self-renewal of cancer stem cells in a subject. In another aspect, the methods described herein kill active or dormant cancer stem cells in a subject. The methods described herein can be used in combination with chemotherapy and/or radiation. The methods described herein are versatile with respect to preventing the relapse of a number of different cancers.
Provided herein is a copper-free, non-toxic click hydrogel that exhibits minimal swelling. The hydrogel may be used as a sealant and/or as a delivery vehicle for local administration of substances of interest, such as therapeutic agents.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
Borreliella and/or diagnosis of Lyme disease are provided. Methods and devices for conducting immunoassays with the chimeric recombinant proteins are also provided.
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C07K 14/20 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
Polymeric drugs for disease therapy are provided. The repeat units of the polymers comprise at least one chemotherapeutic agent, e.g. a cancer drug. The linkages between repeat units are hydrolysable under physiological conditions, e.g. at targeted sites in vivo. Nanoparticles formed from the polymers are also provided.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
63.
CLICK CHEMISTRY HYDROGEL WITH MINIMAL SWELLING AS A LOCAL DELIVERY VEHICLE
Provided herein is a copper-free, non-toxic click hydrogel that exhibits minimal swelling and derived from dibenzocyclooctyne maleimide, poly-ethylene glycol dithiol and azide acrylate. The hydrogel may be used as a sealant and/or as a delivery vehicle for local administration of substances of interest, such as therapeutic agents.
A61K 31/78 - Polymers containing oxygen of acrylic acid or derivatives thereof
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
C07C 13/547 - Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings at least one ring not being six-membered, the other rings being at the most six-membered
64.
RECOGNIZING FREEZING OF GAIT AND DEPLOYING VIBRATION TO MITIGATE SYMPTOMS
Various embodiments of the present disclosure are directed to systems and methods of utilizing a convolutional neural network to detect freezing of gait in patients and provide vibration to return to normal motor function. A system can perform a method of training a convolutional neural network by receiving a video recording; receiving a plurality of timestamp selections indicating when the person demonstrates a freezing of gait event during the video; receiving movement data from the sensing device; extracting domain data from the movement data; providing the plurality of domain data to the convolutional neural network; and deploying the convolutional neural network on a client device. Additionally, a system can be arranged to perform a method of receiving movement data from the sensing device; determining a categorization of the movement by processing the movement data through a convolutional neural network; and directing a vibration delivery device to deliver vibration.
G16H 40/63 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
A filter having antibacterial activity is provided. The filter comprises at least one layer of polymer nanofibers and antibacterial particles positioned on or within the at least one layer of polymer nanofibers, wherein the antibacterial particles comprise a quaternary ammonium compound grafted onto a surface of a metal-organic framework. Methods of manufacturing the filter and decontaminating a fluid are also provided.
A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
A01N 25/08 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
B01D 39/20 - Other self-supporting filtering material of inorganic material, e.g. asbestos paper or metallic filtering material of non-woven wires
66.
USE OF MICRORNA INHIBITION TO PREVENT AND TREAT OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES
Inflammatory processes, particularly those arising from trauma or injury to the region of a bone joint, are causative of osteoarthritis (OA). A composition comprising microRNA-122, microRNA-122 mimic, and/or an inhibitor of microRNA-451 reduces or inhibits inflammatory mediators in articular chondrocytes and related cells. When administered to a subject at risk of developing OA, development of OA and/or progression of OA disease are inhibited, and cartilaginous structures are preserved in the joint. Since joint injury is associated with subsequent development of OA, the treatment is particularly suitable following an acute injury to a joint.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Provided herein are methods for fluid resuscitation of an organ donor. The method includes administering intravenously to the organ donor an organ protectant solution comprising polyethylene glycol polymers (PEG) with a molecular weight of 18,000-40,000 Da at a concentration of 5-15% w/v. The methods are suitable for protecting organs prior to transplantation.
Provided herein are compositions containing guest/host inclusion complexes. In particular, each complex includes S-nitrosoglutathione (GSNO) as the guest and substituted or unsubstituted cyclodextrin as the host, such as alpha cyclodextrin. The compositions may be used as an antibacterial and antithrombotic agent in catheter lock solutions and to deliver nitric oxide to a subject in need thereof.
Disclosed herein are systems and methods for anomaly detection. A distributed physical state estimation system determines low-level state estimates covering respective sections of a cyber-physical system based on raw, high-performance measurement data. Low-level state estimates may be determined for a plurality of sections (substations) concurrently. An upper-level state estimate may be derived from the low-level state estimates. Anomalies pertaining to the system may be detected through analysis of the low-level and upper-level state estimates. The anomalies may be analyzed to determined whether the system is exhibiting behavior indicative of a fault, cyber-attack, and/or compromise.
G06F 21/57 - Certifying or maintaining trusted computer platforms, e.g. secure boots or power-downs, version controls, system software checks, secure updates or assessing vulnerabilities
G06F 11/07 - Responding to the occurrence of a fault, e.g. fault tolerance
G06F 11/34 - Recording or statistical evaluation of computer activity, e.g. of down time, of input/output operation
G06F 21/71 - Protecting specific internal or peripheral components, in which the protection of a component leads to protection of the entire computer to assure secure computing or processing of information
G01R 21/133 - Arrangements for measuring electric power or power factor by using digital technique
Composite materials for simultaneous thermal management and electromagnetic interference screening of radiofrequency-based electronic systems are provided. The materials contain a phase change material and one or more electrically and thermally conductive filler particles. The materials provide a passive system for thermal management and EMI shielding that is lightweight, does not contain moving parts, and does not require an external power supply.
C04B 35/622 - Forming processesProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products
C04B 35/01 - Shaped ceramic products characterised by their compositionCeramic compositionsProcessing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxides
H01C 7/04 - Non-adjustable resistors formed as one or more layers or coatingsNon-adjustable resistors made from powdered conducting material or powdered semi-conducting material with or without insulating material having negative temperature coefficient
A method for treating a subject suffering from chronic multisystem illness, specifically gulf war illness, includes administering to the subject a therapeutically effective amount of a selective inhibitor of solTNF, whereby the subject is treated. In some embodiments, the selective inhibitor of solTNF includes a DN-TNF protein variant and/or a nucleic acid encoding the DN-TNF protein variant. In some embodiments, the DN-TNF protein variant includes XPro1595.
Provided are methods of treating cognitive impairment in a subject suffering from cirrhosis, comprising administering to the subject a therapeutically effective amount of albumin, wherein the subject does not currently suffer from overt hepatic encephalopathy. In particular, the subject has not suffered from overt hepatic encephalopathy within one month of the administering step. The albumin may be administered intravenously.
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventor
Ren, Shunlin
Wang, Yaping
Lin, Weiqi
Brown, James E.
Theeuwes, Felix
Abstract
Aspects of the present disclosure include methods for treating at least one inflammatory condition, such as at least one of dental pulp inflammation, periodontal disease, skin inflammation, psoriasis, ulcerative colitis, osteoarthritis, inflammatory bowel disease (IBD), Crohn's disease, irritable bowel syndrome (IBS), Alzheimer's disease, Parkinson's disease, pancreatitis (acute and/or chronic), hepatitis (viral and/or non-viral), atherosclerosis, myocarditis, idiopathic pulmonary disorder (IPD), chronic obstructive pulmonary disorder (COPD), pneumonia, chronic inflammatory lung disease, bronchitis, asthma, chronic kidney disease (CKD), nephritis, sepsis, ankylosing spondylitis, diverticulitis, and fibromyalgia. In some cases, the at least one inflammatory condition is associated with Epstein-Ban virus infection. In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
74.
FORMULATIONS FOR ADMINISTERING LAAM, norLAAM AND dinorLAAM AND METHODS OF THEIR USE TO TREAT OPIOID USE DISORDER
Rapid-release formulations for administering Levo-alpha-acetylmethadol (LAAM), norLAAM and dinorLAMM and, optionally, magnesium, are provided. The formulations include solid i) core-shell oral dosage forms delivered in capsules or tablets, and ii) electrospun nano/microfiber buccal film dosage forms. Methods of the use of the formulations to treat opioid use disorder (OUD) and pain are also provided.
A self-cleaning face covering is provided. The face covering includes a fabric layer having a resisitive heating element disposed on the fabric; and an infrared reflective layer arranged between the fabric layer and an inner surface of the face covering configured to reduce heat transfer to the inner surface. Methods of cleaning the face covering are also provided.
A41D 13/005 - Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches with controlled internal environment with controlled temperature
76.
A FACTOR H BINDING PROTEIN B (FHBB) BASED CHIMERIC VACCINE FOR THE PREVENTION AND TREATMENT OF PERIODONTAL DISEASE
Provided herein are recombinant Factor H Binding Protein B (FhbB) chimeric proteins comprising several different mutant variants of the Treponema denticola Factor H binding protein B (FhbB). The mutant variants cannot bind Factor H. The chimeric proteins are used to vaccinate subjects against periodontal disease either systemically and/or by direct application of antibodies generated against the chimeric proteins to the oral cavity (e.g. the gums) of a patient to prevent and/or treat periodontal disease.
Disclosed are various embodiments for training physicians to perform surgeries or procedures. To do this, a display can render a three-dimensional model of human anatomy and a virtual surgical instrument in a virtual space. A computing device can receive movement input from an input device. Based on the movement input from the input device, the computing device can cause the virtual surgical instrument to move on the display. The computing device can detect a collision between the virtual surgical instrument and the three-dimensional model of human anatomy in the virtual space and, in response, the computing device can direct the input device to provide haptic feedback. Various other features are disclosed that further aid in the training of a surgeon to perform surgeries or procedures.
Examples include spatially positioning, in a three-dimensional (3D) space, a conductive coil and a living subject in a 3D spatial relation in which a target 3D region of the living subject's tissue is within a designated 3D electric field formation region for the conductive coil. An energizing source feeds a low frequency (LF) modulated high frequency (HF) carrier voltage to terminals of the conductive coil. This urges a corresponding LF modulated HF coil current, of maximum magnitude MA, through the conductive coil. The HF frequency of the HF coil current produces a magnetic flux with a corresponding HF related rate of change. Optionally, a secondary coil feeds an unmodulated HF signal that spatially overlaps the modulated HF signals.
Microdevices and methods provide for separating cells of a single type from a mixed biological sample containing multiple types of cells. A single microdevice may be configured to allow for separating out cells into multiple groupings, each grouping containing cells of only one cell type. Transfer of separated cells off the microdevice is performed by physical separation of part of the microdevice from a remainder of the microdevice. This step advantageously minimizes accidental cell losses in the transfer. Subsequent analysis may then be performed using non-microfluidic equipment and techniques.
NLRP3 selective inhibitors (NSIs) as anti-inflammatory agents are provided, as are methods of using NSIs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, acute myocardial infarction, heart failure, arthritis, diabetes, gout, COVID-19, and autoinflammatory diseases.
C07D 231/02 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
C07D 233/02 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A61P 25/00 - Drugs for disorders of the nervous system
Devices to detect analytes (e.g., charged species such as ions) in samples are provided as are methods for their use. The devices comprise a tube or container comprising a water-immiscible sensing oil phase comprising at least one sensing chemical that binds the at least one analyte. The tube further receives an aqueous sample. Upon mixing of the two immiscible phases, the analyte partitions into the oil phase and binds to the sensing chemical, delectably changing the optical properties of the sensing chemical (or of an associated reporter molecule). Detection of the changes permits quantification of the amount or concentration of analyte in the sample without optical interference from the sample. The devices are suitable for home use and other decentralized settings.
G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators
G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
82.
METHODS FOR DETECTING INDOLE, AN INDOLE PRODUCING BACTERIUM, OR AN INDOLE PRODUCING CHEMICAL
In an example method for detecting indole, an indole producing bacterium, or an indole producing chemical, a polymeric detection tool is exposed to a sample and the polymeric detection tool is monitored for a red color change. The polymeric detection tool includes an acidic and oxygen soluble polymer and a nitrosation agent impregnated in walls of the acidic and oxygen soluble polymer. This example method can be used for detecting an indole producing bacterium in a body fluid sample.
Containment units, dry powder inhalers, delivery systems, and methods for the same are disclosed. Exemplary devices are configured to have inlets and outlets which are formed with the containment walls of a containment unit. Air jets formed by the configuration of inlet(s) and outlet(s) inside the containment unit create significant turbulence and deaggregate the powder. Delivery system components downstream of the containment unit may integrate the exiting aerosol plume with a low flow nasal cannula air stream for delivery to a subject.
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventor
Ren, Shunlin
Wang, Yaping
Lin, Weiqi
Abstract
Aspects of the present disclosure include methods for treating at least one autoimmune condition, such as at least one of hepatitis, multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. In some cases, the at least one autoimmune condition is associated with Epstein-Barr virus infection. In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Provided are a Native Cell Membrane Nanoparticle (NCMN) system and methods of using the NCMN polymers to extract and/or purify one or more membrane proteins. The NCMN system includes at least one NCMN polymer and one or more membrane proteins in their native lipid bilayer membrane. A method of using the NCMN system to extract or isolate the one or more membrane proteins in the form of NCMN system without the use of a detergent while maintaining the protein’s native structure and functional activity is provided.
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventor
Ren, Shunlin
Wang, Yaping
Lin, Weiqi
Brown, James E.
Blaschke, Terrence
Abstract
Aspects of the present disclosure include methods for treating at least one of insulin resistance, diabetes, and prediabetes, and, optionally, also non-alcoholic steatohepatitis (NASH). In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25- hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27- hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24- hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
88.
AEROSOL-ASSISTED SYNTHESIS OF CRYSTALLINE TUNGSTEN BRONZE PARTICLES
Provided herein are methods for producing crystalline tungsten bronze oxide particles. The method may include atomizing a liquid solution comprising an alkali metal precursor and a tungsten precursor to produce droplets; mixing the droplets with one or more gaseous flows to produce a combined flow; flowing the combined flow through a heated reactor to provide crystalline tungsten bronze oxide particles having the formula MxWO3, wherein M is the alkali metal; and collecting the particles.
A series of non-peptide opioid receptor modulators having the general formula: (I) is provided. In the formula: R = (II) * is a chiral carbon; M is a saturated or unsaturated, branched or unbranched, substituted or unsubstituted alkyl chain from 0-10 atoms in length; X1, X2, X3, X4, or X5 are independently, C, N, O, or S; and R is attached to M by any of X1, X2, X3, X4, or X5. The compounds are used to treat disorders related to opioid receptor functions such as opioid addiction, opioid overdose, pain and constipation caused by opioid use.
C07D 489/00 - Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
Provided are systems and methods of identifying the functional characteristics and operational settings of any electronic inhalants or apparatuses that are designed to provide nicotine vapors to a user. The system includes a mobile device having a built-in camera to receive images of a nicotine delivery device, a system of remote backend servers with at least one image database for identifying the nicotine delivery device, and at least one processor for calculating an amount of nicotine delivered by the nicotine delivery device.
Methods for detecting length polymorphisms in a DNA sample are provided. The methods include steps of amplifying a target region of the DNA in the sample, wherein the DNA sample is diluted prior to the amplifying step to provide a plurality of amplified samples in which 0 or 1 target DNA strand is amplified in each amplified sample and wherein at least one amplified sample includes 1 target DNA strand; depositing the plurality of amplified samples onto a surface; imaging the plurality of amplified samples deposited on the surface using atomic force microscopy (AFM) to determine an amplicon length distribution; comparing the amplicon length distribution to a corresponding amplicon length distribution obtained from a reference DNA sample that does not contain a length polymorphism in the target region; and detecting a length polymorphism in the target region of the DNA sample when the amplicon length distribution is distinct from the corresponding amplicon length distribution.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
Low-cost and earth abundant, Ni1−xMox alloy nanocrystals, with sizes ranging from 18-43 nm and varying Mo composition (0.0-11.4%), were produced by a colloidal chemistry method for alkaline HER reactions. For a water splitting current density of ˜10 mA/cm2, these alloys demonstrate over-potentials of −62 to −177 mV, which are comparable to commercial Pt-based electrocatalysts (−68 to −129 mV). The cubic Ni0.934Mo0.066 alloy nanocrystals exhibit the highest activity as alkaline HER electrocatalysts, outperforming commercial Pt/C (20 wt %) catalyst.
C22C 19/03 - Alloys based on nickel or cobalt based on nickel
B22F 9/24 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
A method of delivering an active ingredient to a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a formulation comprising biodegradable, polymeric microparticles and an active ingredient selected from the group consisting of levo-alpha-acetylmethadol (LAAM), nor-LAAM, and dinor-LAAM, wherein the active ingredient is part of a hydrophobic ion-pairing (HIP) complex and wherein the HIP complex is associated with the microparticles. Sustained release formulations containing an active ingredient are also provided.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
94.
USE OF OXYGENATED CHOLESTEROL SULFATES FOR CANCERS AND NON-CANCEROUS TRANSFORMATIONS RELATED TO EPSTEIN-BARR VIRUS
The United States Government as Represented by the Department of Veterans Affairs (USA)
Inventor
Ren, Shunlin
Wang, Yaping
Lin, Weiqi
Abstract
Aspects of the present disclosure include methods for treating at least one of cancer and non-cancerous transformation related to Epstein-Barr virus, such as at least one of Hodgkin's lymphoma, soft tissue sarcoma, leiomyosarcoma, nasopharyngeal carcinoma, Burkitt's lymphoma, T-cell lymphoma, gastric carcinoma, invasive breast cancer, and hierarchically organized carcinoma. Hierarchically organized carcinomas include, but are not limited to, pancreatic ductal adenocarcinoma, urothelial cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer, esophagus cancer, breast cancer, thyroid cancer, oral cancer, cervical cancer, ovarian cancer, and liver cancer. In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Provided are stimulation devices for improving ambulatory activity of a subject in need thereof. The device includes a foot covering for holding two battery-operated tactile actuators on a metatarsal region and an ankle region of the wearer's foot. The foot covering also includes a detachable material for housing and securing the two tactile actuators and a pouch region for holding electronics.
A61H 23/02 - Percussion or vibration massage, e.g. using supersonic vibrationSuction-vibration massageMassage with moving diaphragms with electric or magnetic drive
96.
USE OF OXYGENATED CHOLESTEROL SULFATES FOR TREATING NEUROLOGICAL CONDITIONS, NEURODEGENERATIVE DISEASES, AND ADDICTION
THE UNITED STATE GOVERNMENT as represented by THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventor
Ren, Shunlin
Wang, Yaping
Lin, Weiqi
Brown, James E.
Theeuwes, Felix
Abstract
Aspects of the present disclosure include methods for treating at least one of depression, neurodegenerative disease, multiple sclerosis, Parkinson's disease, spinocerebellar degeneration, Friedreich ataxia, ataxia-telangiectasia, progressive supranuclear palsy, Huntington's disease, striatonigral degeneration, olivopontocerebellar atrophy, Shy-Drager syndrome, schizophrenia, schizoaffective disorder, manic-depression (bipolar) disorder, disturbed or abnormal circadian entrainment, childhood Alice in Wonderland syndrome, childhood acute cerebellar ataxia, and Alzheimer's disease. In some instances, methods include treating an addiction to a drug, such as alcohol addiction, cocaine addiction or amphetamine addiction. In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25-hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27-hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24-hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
Disclosed are various approaches for generating synthetic computer tomography (CT) images using magnetic resonance imaging A patient body outline (PBO) of a patient is obtained. Then, a magnetic resonance image set in a limited field of view (MRI-in-LFOV) of the patient is converted into a synthetic computed tomography (CT) image set in limited field of view (syn-CT-in-LFOV) of the patient. Next, the syn-CT-in-LFOV is expanded to a synthetic CT image set in full field of view (syn-CT-in-FFOV) of the patient based at least in part on the PBO.
G06T 11/60 - Editing figures and textCombining figures or text
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
98.
METHODS FOR DECELLULARIZING ANIMAL TISSUE AND BIOINKS DERIVED THEREFROM
Fluorescence resonance energy transfer (FRET)-based nucleic acid sensors and methods of their use for detecting nucleic acids are provided. The sensors are highly sensitive and detect nucleic acids at the femtomolar (fM) level, without the need for labeling and amplification.
